Bardia A et al. Sacituzumab govitecan in metastatic breast cancer. Reply. N Engl J Med 2021;385(3):e12. Abstract

Beyerlin K et al. The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population. J Oncol Pharm Pract 2020;[Online ahead of print]. Abstract

Cortes J et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 2020;396(10265):1817-28. Abstract

Jacob S et al. The use of serial circulating tumor DNA to detect resistance alterations in progressive metastatic breast cancer. Clin Cancer Res 2021;27(5):1361-70. Abstract

Litton JK et al. Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study. ASCO 2021;Abstract 505.

Reynolds KL et al. The art of oncology: COVID-19 era. Oncologist 2020;25(11):997-1000g. Abstract

Spring LM et al. Sacituzumab govitecan for metastatic triple-negative breast cancer: Clinical overview and management of potential toxicities. Oncologist 2021;26(10):827-34. Abstract

Spring LM et al. Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer (NeoSTAR). SABCS 2020;Abstract OT-03-06.

Spring LM et al. Case 22-2020: A 62-year-old woman with early breast cancer during the Covid-19 pandemic. N Engl J Med 2020;383(3):262-72. Abstract

Tung NM et al. Adjuvant PARP inhibitors in patients with high-risk early-stage HER2-negative breast cancer and germline BRCA mutations: ASCO hereditary breast cancer guideline rapid recommendation update. J Clin Oncol 2021;39(26):2959-61. Abstract

Tutt ANJ et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 2021;384(25):2394-405. Abstract

Vidula N et al. Phase II multicenter study of talazoparib for somatic BRCA1/2 mutant metastatic breast cancer. ASCO 2021;Abstract TPS1110.

Vidula N et al. Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast cancer. Oncotarget2021;12(2):63-5. Abstract

Zubiri L et al. Temporal trends in inpatient oncology census before and during the COVID-19 pandemic and rates of nosocomial COVID-19 among patients with cancer at a large academic center. Oncologist 2021;26(8):e1427-33. Abstract